United Therapeutics (NASDAQ:UTHR) CFO James Edgemond Sells 10,000 Shares

May 16, 2026 by InsiderTrades.com

Key Points

United Therapeutics CFO James Edgemond sold 10,000 shares on May 14 at an average price of $574.47, totaling about $5.74 million. After the sale, he still held 18,876 shares, but his ownership fell by 34.63%.
The CFO has been actively selling shares in recent weeks, with multiple 10,000-share transactions and additional smaller sales disclosed in SEC filings. The article also notes that CEO Martine Rothblatt and another director recently sold shares as well.
Despite the insider selling, analyst sentiment remains constructive: several firms maintain Buy or Outperform ratings, and the stock’s average price target is around $619.42. United Therapeutics most recently missed quarterly EPS and revenue estimates, however.

United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CFO James Edgemond sold 10,000 shares of the stock in a transaction on Thursday, May 14th. The stock was sold at an average price of $574.47, for a total value of $5,744,700.00. Following the transaction, the chief financial officer owned 18,876 shares of the company's stock, valued at $10,843,695.72. This represents a 34.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

The Top 3 Stock Picks at the World’s Greatest Hedge Fund

James Edgemond also recently made the following trade(s):

On Monday, May 11th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $573.03, for a total value of $5,730,300.00.
On Thursday, May 7th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $578.58, for a total value of $5,785,800.00.
On Monday, May 4th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $576.93, for a total value of $5,769,300.00.
On Thursday, April 30th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $572.61, for a total value of $5,726,100.00.
On Monday, April 27th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $568.83, for a total value of $5,688,300.00.
On Wednesday, April 22nd, James Edgemond sold 364 shares of United Therapeutics stock. The stock was sold at an average price of $575.85, for a total value of $209,609.40.
On Thursday, April 23rd, James Edgemond sold 9,636 shares of United Therapeutics stock. The stock was sold at an average price of $572.21, for a total value of $5,513,815.56.
On Monday, April 20th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $577.86, for a total value of $5,778,600.00.
On Thursday, April 16th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $577.18, for a total value of $5,771,800.00.
On Monday, April 13th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $574.88, for a total value of $5,748,800.00.

United Therapeutics Stock Performance

Shares of UTHR stock opened at $568.58 on Friday. The stock's fifty day moving average is $558.07 and its 200-day moving average is $507.08. The stock has a market capitalization of $24.14 billion, a PE ratio of 20.99, a PEG ratio of 1.82 and a beta of 0.60. United Therapeutics Corporation has a 52 week low of $272.12 and a 52 week high of $609.35.

Liquidia: Court victory the awakening of an industry giant?

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing the consensus estimate of $7.00 by ($1.18). The business had revenue of $781.50 million for the quarter, compared to the consensus estimate of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.United Therapeutics's revenue for the quarter was down 1.6% on a year-over-year basis. During the same quarter in the previous year, the company posted $6.63 EPS. As a group, analysts forecast that United Therapeutics Corporation will post 27.64 earnings per share for the current fiscal year.

More United Therapeutics News

Here are the key news stories impacting United Therapeutics this week:

Neutral Sentiment: CEO Martine Rothblatt sold 9,500 shares for about $5.5 million, trimming her stake by 19%; CFO James Edgemond also sold 10,000 shares for about $5.7 million, reducing his ownership by 34.6%. These sizable insider transactions can make investors cautious about near-term sentiment. Article Title
Neutral Sentiment: Director Nilda Mesa also sold 258 shares, a smaller transaction that adds to the recent insider selling trend. Article Title
Positive Sentiment: HC Wainwright maintained a Buy rating and a $660 price target, despite trimming its FY2030 earnings estimate slightly. Broader analyst coverage remains constructive, with a consensus rating of Moderate Buy and a target around $619.42, which may help support the stock. Article Title

Hedge Funds Weigh In On United Therapeutics

Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential

Hedge funds have recently added to or reduced their stakes in the company. Torren Management LLC bought a new position in United Therapeutics in the fourth quarter valued at about $26,000. Activest Wealth Management boosted its holdings in United Therapeutics by 1,400.0% in the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company's stock valued at $29,000 after acquiring an additional 56 shares during the last quarter. Entrust Financial LLC bought a new position in United Therapeutics in the fourth quarter valued at about $31,000. International Assets Investment Management LLC boosted its holdings in United Therapeutics by 426.7% during the first quarter. International Assets Investment Management LLC now owns 79 shares of the biotechnology company's stock worth $45,000 after buying an additional 64 shares during the last quarter. Finally, Wilmington Savings Fund Society FSB boosted its holdings in United Therapeutics by 125.6% during the third quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company's stock worth $37,000 after buying an additional 49 shares during the last quarter. Institutional investors own 94.08% of the company's stock.

Analysts Set New Price Targets

UTHR has been the topic of several research analyst reports. Jefferies Financial Group restated a "buy" rating on shares of United Therapeutics in a report on Monday, March 2nd. Royal Bank Of Canada decreased their price target on United Therapeutics from $707.00 to $701.00 and set an "outperform" rating on the stock in a report on Thursday, May 7th. Morgan Stanley set a $516.00 price target on United Therapeutics in a report on Thursday, May 7th. Wells Fargo & Company upgraded United Therapeutics from an "equal weight" rating to an "overweight" rating and raised their price target for the company from $575.00 to $735.00 in a report on Thursday, May 7th. Finally, Raymond James Financial started coverage on United Therapeutics in a report on Friday, April 10th. They issued an "outperform" rating and a $700.00 price target on the stock. Eleven analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $619.42.

Check Out Our Latest Stock Analysis on United Therapeutics

United Therapeutics Company Profile

(Get Free Report)

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.